You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back


Don’t let asthma control your patients

Keep asthma tamed through proactive control that lasts with Relvar.

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting β2-agonists.
  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.1

Why choose Relvar?

Tick icon

25% more patients see improvement vs other commonly used ICS/LABAs*2

24-H icon

Sustained efficacy for 24 hours and long-lasting anti-inflammatory effect3-5

Ellipta device icon

Good adherence with an easy-to-use device1,6,7

Proactive regular dosing (PRD) with Relvar for asthma control

Who can benefit from Relvar?

‌Hypothetical patients used for illustrative purposes.

Discover more about Relvar

Important Product Information

Patient information

Summary of product characteristics


*The primary endpoint was the proportion of patients who achieved an improvement in ACT score from baseline of ≥3 or a total ACT score of ≥20, in patients in the PEA population initiated on Relvar vs continuing on usual care (ICS or ICS/LABA) at 24 weeks. The primary endpoint was met (p<0.0001). Data presented are from a subset of patients prescribed ICS/ LABA at baseline who were initiated on Relvar or continued on their ICS/LABA. Data showed a relative difference of 25% and an absolute difference of 14%.2 In this study there was no difference in serious adverse events reported between Relvar and usual care. The most common serious adverse events of special interest were cardiovascular disease, asthma and bronchospasm, and pneumonia.2


ACT, Asthma Control Test; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; PEA, primary effectiveness analysis; PRD, proactive regular dosing. 

  1. Global Datasheet Fluticasone furoate/vilanterol: v11, May 2021.
  2. Woodcock A, et al. Lancet 2017;390:2247–2255.
  3. Bernstein DI, et al. J Asthma 2015;52:1073–1083.
  4. Braithwaite I, et al. Respir Med 2016;119:115–121.
  5. Bardsley G, et al. Respir Res 2018;19:133.
  6. Svedsater H, et al. NPJ Prim Care Respir Med 2014;24:14019.
  7. Parimi M, et al. Adv Ther 2020;37:2916–2931.
  8. Daley-Yates PT. Br J Clin Pharmacol 2015;80:372–380.

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

PM-IE-FFV-WCNT-230005 June 2023